Kenneth Locke and Ian Smith, industry leaders in Cell and Gene Therapy, join as iVexSol advisors
iVexSol Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
Viral vector manufacturing and transduction processes today are lengthy and inconsistent
Lexington, MA – (March 22, 2022) iVexSol, Inc., a lentiviral vector manufacturing company is pleased to announce the appointment of Sean Brown as Senior Vice President of Operations.
LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
A gateway to explore a next generation stable lentiviral vector manufacturing technology
FOR IMMEDIATE RELEASE
Technology targets critical shortage of viral vectors for the rapidly
expanding field of cell and gene therapeutics